Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 245 results for "Victoza"

BRIEF-Novo Nordisk presents new Victoza, Ryzodeg results

Dec 1 Novo Nordisk * Says new findings from a network meta-analysis show that treatment with Victoza provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to SGLT-2 inhibitors * The treatment was ... Reuters UK, 3 hours ago

8 images for Victoza

Bidness Etc, 2 weeks ago
Pharmafile, 2 weeks ago, 1 week ago
BioPharma Dive, 3 weeks ago
Drug Discovery and Development, 3 weeks ago
The Malaysian Times, 3 weeks ago
One News Page United Kingdom, 3 weeks ago
BioPharma Dive, 3 weeks ago

Human medicines European public assessment report (EPAR): Victoza, liraglutide, Revision: 13, Authorised

This is a summary of the European public assessment report (EPAR) for Victoza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...
 European Medicines Agency1 week ago
Bidness Etc

Victoza Brings About No Effects To Help Control Heart Failure

At a meeting of the American Heart Association (AHA) in Orlando, it was announced that Victoza (liraglutide) had failed to bring about any positive changes in patients with advanced heart failure, after a clinical trial of 300 patients with type 2 ...
 Bidness Etc2 weeks ago Novo Nordisk looks to HEOR data to back Victoza  Pharmafile2 weeks ago Novo's Victoza fails the 'Jardiance test,' doesn't improve heart outcomes in trial  BioPharma Dive3 weeks ago Novo Nordisk diabetes drug fails to help heart failure  Pharma Focus Asia3 weeks ago

Positive new cost data on Novo Nordisk's Victoza

New findings from a health economics and outcomes research (HEOR) analysis demonstrated that Victoza (liraglutide) 1.2mg is cost-effective for the treatment of type 2 diabetes in the UK market when compared to lixisenatide (Lyxumia from Sanofi) and ...
 Pharma Letter3 weeks ago Victoza® (liraglutide) is cost-effective vs. lixisenatide and cost-saving vs. exenatide in the UK  Ulitzer3 weeks ago Victoza(R) (liraglutide) is cost-effective vs. lixisenatide an…  Asia PR News3 weeks ago NOVO NORDISK A/S : Victoza® (liraglutide) is cost-effective vs. lixisenatide and cost-saving vs. exenatide in the UK  4 Traders3 weeks ago

Novo weighs options before crucial Victoza heart study data

By Ben Hirschler LONDON (Reuters) - Novo Nordisk is considering options ahead of key heart safety data for its diabetes drug Victoza and could run a further clinical study if necessary, the Danish company's research head said on Wednesday. The ...
 Yahoo! Canada3 weeks ago Top 10 US pharma advertising spenders, September 2015  Pharmafile1 month ago

UK investigators publish small, promising study of Victoza for NASH

'; if(pArray.length >= 4) { i=2; } else if(pArray.length >= 3) { i=2; inline = ''; } else if(pArray.length >= 2) { i=1; inline = ''; } else if(pArray.length === 1) { i=0; inline = ''; } $('#librarydrawer_story_container script').each(function() { ...
 Fierce Biotech Research6 days ago U.K. investigators publish small, promising study of Victoza for NASH  Fierce Biotech Research6 days ago
BioPharma Dive

The Jardiance effect: Novo hopes Victoza will show heart benefit, but wary of CV study design

Dive Brief: In August, new data from Eli Lilly and Boehringer Ingelheim (BI) showing that Jardiance ( empagliflozin) decreases risk of cardiovascular (CV)-related events and deaths, was announced . This news has put pressure on other diabetes ...
 BioPharma Dive3 weeks ago Jardiance scores more cardiovascular outcomes data  Pharmafile3 weeks ago

$50 Million Plus Royalties Deal Indicates Bright Future For Oramed's Oral Insulin

Summary Oramed's deal with China's leading insulin manufacturer and technology incubator Hefei aims to bring novel medicine to the large Chinese diabetes market. Deal includes ongoing 10% royalty in a multi-billion dollar industry. Oramed's ...
 Seeking Alpha8 hours ago ORAMED PHARMACEUTICALS, INC. : $50 Million Plus Royalties Deal Indicates Blockbuster Future for Oramed's Oral Insulin  4 Traders8 hours ago

FxPro Celebrates Double Award Triumph

· LONDON, Dec. 1, 2015/PRNewswire-AsiaNet/ For yet another year, online broker FxPro proudly receives worldwide recognition as a top-class financial service provider after being honoured with major prestigious accolades. Following ...
 Asia PR News2 hours ago

New data highlight impact of post-meal hyperglycaemia on peopl…

Date: Tuesday, December 1, 2015 18:00 GMT · VANCOUVER, Canada, December 2 /PRNewswire-AsiaNet/ — This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. ...
 Asia PR News4 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
Get updated on latest news & your favorite topics right in your inbox!
More     Less